MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced it will move its national headquarters to a 12,600-square foot office in the Westlake Landmark office park in Westlake Village. MannKind—the manufacturer and seller of Afrezza insulin inhalation powder—moved from Valencia to a Conejo Valley region known for its strong biopharmaceutical presence.
MannKind focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Afrezza is the company’s first, FDA-approved prescription product being marketed nationwide. The company employees 153 full-time employees, but didn’t say how many will be working at the Westlake office.
“MannKind is a dynamic, fast-moving and rapidly growing company,” MannKind chief executive Michael Castagna said.
“To fuel this growth, we need to add more talented people to our team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top talent,” the CEO said. “We’re excited to be a member of the Westlake Village and greater Conejo Valley business community,” Castagna said.
A statement from the company says it has “shattered the paradigm of diabetes management” with Afrezza, the only inhalable insulin that improves glycemic management in adults with diabetes. The company says it has additional therapeutic products in its pipeline that use a dry powder formulation as a drug delivery platform.
Following a $368 million loss in 2015, MannKind turned a $125.6-million profit in 2016, the first year in the black since 2012, records show.
MannKind operates a manufacturing and product development facility in Danbury, Conn., and employs medical and field sales representatives across the U.S.
Acorn staff report